Caidya’s John Wang Named Chair of China CDISC Coordinating Committee; Medidata Accreditation Underscores Data Management Excellence
RALEIGH, N.C.; July 22, 2025 – Caidya a global, technology-enabled clinical research organization (CRO), today announced that John Wang, Senior Director of Statistical Programming, has been appointed Chair of the China CDISC Coordinating Committee (C3C) for the 2025–2028 term. This prestigious appointment highlights Caidya’s leadership in data standardization and innovation in global clinical research. A CDISC-authorized SDTM instructor since 2016, Wang will lead the C3C in driving CDISC adoption and fostering regulatory collaboration across China.
Caidya’s commitment to data excellence was further underscored by its recent Site Cloud accreditation from Medidata. This designation enables Caidya to deliver eCRF PDFs and audit trails electronically, significantly reducing cycle times and increasing operational efficiency. The accreditation also supports enhanced EDC compliance tracking and seamless eTMF integration, reinforcing Caidya’s ability to work faster and smarter across global sites
These reflect Caidya’s stature as a trusted partner for sponsors seeking innovative and reliable data management solutions in clinical trials.
About Caidya
Caidya is a global, full-service contract research organization (CRO) built for biopharma innovators developing life-changing therapies. Conducting studies in over 50 countries and a strong presence across North America, Europe, and Asia-Pacific, Caidya delivers a superior customer experience through personalized solutions that span the full clinical development lifecycle. From pre-IND strategy through study closeout and post-marketing, Caidya brings therapeutic expertise, operational agility, and an ownership mindset to every partnership. Specializing in complex, multi-regional trials across oncology, hematology, rare disease, pediatrics, cardiovascular, and more, Caidya consistently delivers on timelines and outcomes. Working shoulder to shoulder as partners, we bring expertise relevant to your study, agility to navigate complex trials, and global access to patients, yielding the high-quality data you need to make informed decisions – for today, and tomorrow.
MEDIA CONTACT:
Roger Boutin
VP, Corporate Marketing, Caidya